Trial Profile
Randomized, controlled trial of the effect of luseogliflozin in type 2 diabetic patients with fatty liver
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2019
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary) ; Metformin
- Indications Fatty liver; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 13 Jun 2017 Primary endpoint (A liver attenuation index at unenhanced CT 24 week after administration) has been met as per the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 03 Feb 2015 New trial record